Avid Bioservices Inc (CDMO)

[dia76ca]

I found the reference to Merck KGaA interesting in the article.

"PPHM's announcement that their phase 2b lung cancer trial of bavituximab resulted in survival times double that of standard care. Even the King of the shorts, although skeptical at first, said he would not short PPHM and said the results were assume, if true. He could not find a "smoking gun" against the results which followed gold standard practices and said it could go to 10 on partnershipe news. I think Merck KGaA is interested and I will detail why in a future post."

Merck KGaA is not the giant Merck but is a very profitable family owned pharma. They partnered with THLD with a contract that has many of the elements that PPHM is seeking. THLD received about $525 million in upfront and developmental milestones and co-partnering rights in the US. PPHM has trials going in many more indications than THLD and so far has better MOS data(but in a different but equally tough indication). I would expect $1 billion in upfront and milestones if they partnered with Merck KGaA.